

Science Evidence Advice

Weekly Surveillance Report

10 December 2024

Science Evidence Advice (SEA)

gov.wales

Providing evidence and advice for Health and Social Services Group on behalf of the Chief Scientific Advisor for Health

Science Evidence Advice: Weekly Surveillance Report

A. Top Line Summary

- Overall, COVID-19 confirmed case admissions to hospital **increased** in the most recent week.
- COVID-19 cases who are inpatients have **increased** in the most recent week.
- RSV activity in children under 5 years has **decreased** in the most recent week.
- Influenza cases have **increased** in the latest week.
- Whooping Cough notifications have **decreased** slightly in the most recent week.
- Scarlet Fever notifications **remained stable** in the most recent week.
- Norovirus confirmed cases have **increased** in the most recent reporting week.

B. Acute Respiratory Infections Situation Update

B.1 COVID-19 Situation Update

COVID-19 case numbers have decreased in recent weeks.

- At a national level, the weekly number of confirmed case admissions to hospital increased and the number of cases who are inpatients has also increased in week 48.
- As at 1 December 2024 the number of confirmed cases of community acquired COVID-19 admitted to hospital increased to **36** and there was an increase to **251** in-patient cases of confirmed COVID-19, **4** of whom were in critical care compared to **235** and **1** in the previous week.
- The overall proportion of samples testing positive in hospitals and sentinel GP practices increased to **5.8%** in the most recent week (4.9% in the previous week). Consultations with sentinel GPs for ARI decreased in the most recent week and confirmed cases of COVID-19 in sentinel GP patients also decreased.
- During week 48, according to European Mortality Monitoring (EuroMoMo) methods, 'no excess deaths' were reported in the weekly number of deaths from all causes in Wales.
- Between weeks 43 and 48, KP.3* from the Pango lineage was the most dominant variant in Wales, accounting for **43.7%** of all sequenced cases. The emerging XEC variant is second highest accounting for **27.3%** of cases.
- The number of Ambulance calls recorded referring to syndromic indicators decreased from **2,391** in the previous week to **2,362** in the latest reporting week.

SEA Surveillance Report

• During week 48, 2024, **3** ARI outbreaks were reported to the Public Health Wales Health Protection Team. Two outbreaks were for Influenza and one was for RSV. All three were in a residential home setting.




Figure 1: Samples from hospital patients submitted for RSV, Influenza and SARS-CoV2 testing only, by week of sample collection, Week 48, 2023 to Week 48, 2024 (source: <u>PHW</u>)

COVID-19 Short Term Projections

The Science Evidence Advice team at Welsh Government have produced short term projections (STPs) for COVID-19 which can be produced nationally and at the Local Health Board unit. STPs project 2 weeks forward from 8 weeks of current data, and do not explicitly factor in properties of the infectious disease, policy changes, changes in testing, changes in behaviour, emergence of new variants or rapid changes in vaccinations.

The COVID-19 STPs uses admissions data from PHW until 23 November 2024 to make short term projections for COVID-19 weeks forward (14 December 2024). The black dots show the actual data points while the white line is the best fit from the most recent projection. The colour shadings represent the 95% confidence interval of the projections with light purple showing the most recent projection and the dark purple showing the oldest. The STPs for Wales show that COVID-19 admissions are projected to continue to slightly decrease over the next two week period (Figure 2). Figure 3 shows that COVID-19 admissions are projected to increase slightly in Betsi Cadwaladr health board over the next two weeks.





Figure 2: Short Term Projections for COVID-19 hospital admissions in Wales (data until 30 November 2024)

Figure 3: Short Term Projections for COVID-19 hospital admissions in Wales Health Boards (data until 30 November 2024)



Swansea University Mid Term Projections (MTPs) for COVID-19

The latest available Swansea University MTPs using data up to the end of January 2025 indicate a decline in COVID-19 non-ICU hospital admissions through to the end of November and into December and then plateauing into January 2025. ICU admissions are projected to remain at low levels as are deaths caused by COVID-19.

Notes: In the charts below, red crosses represent actual COVID-19 cases data. The blue line represents the central modelling estimate. The blue ribbon represents the confidence intervals, with the darker blue ribbon indicating the 25th to 75th percentiles, and the 95% confidence limits in the lighter ribbon.




Figure 4: Daily COVID-19 hospital admissions, projected to end January 2025

Figure 5: Daily COVID-19 ICU admissions, projected to end January 2025






Figure 6: Daily COVID-19 deaths, projected to projected to end January 2025



B.2 Influenza Situation Update

PHW report that **influenza** is circulating and we are at the start of the influenza season. The number of confirmed cases of community acquired influenza admitted to hospital increased to **99** in the most recent week (from **49** in the previous week). There were **176** hospital inpatient cases of confirmed influenza, **11** of whom were in critical care (compared to **62** and **5** in the previous week). In week 48 there were 27 confirmed cases of influenza A(H3N2), 58 cases of influenza A(H1N1)pdm09, 226 influenza A untyped and 6 influenza B (Figure 7).

Figure 7: Influenza subtypes based on samples submitted for virological testing by Sentinel GPs and community pharmacies, hospital patients, and non-Sentinel GPs, by week of sample collection, Week 48, 2023 to Week 48, 2024 (source: <u>PHW</u>)



Consultations for influenza-like illness (ILI) with sentinel GPs increased compared to the previous week, and are approaching the low intensity threshold. There were 7.6 ILI consultations per 100,000 practice population in the most recent week, an increase compared to the previous week (3.7 consultations per 100,000) (Figure 8).






Figure 8: Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (source: PHW)

B.3. Respiratory Syncytial Virus (RSV) update


RSV is circulating, with activity at **very high** intensity levels in children aged up to 5 years old. Incidence per 100,000 population in children aged up to 5y decreased to **123.3** in the most recent week. The number of confirmed cases of community acquired RSV admitted to hospital decreased to **90** in the most recent week (**95** in the previous week). In the most recent week, there were **117** in-patient cases of confirmed RSV, five of whom were in critical care.






B.4 Whooping Cough (Pertussis)

Figure 10 below shows that whooping cough notifications up to the end of week 48 decreased and remain at low levels. Lab confirmations continue to be at very low levels and have remained stable in the latest week.





B.5 iGAS and Scarlet Fever

The number of iGAS notifications are currently low, remaining at seasonally expected levels. Scarlet Fever notifications have **remained stable** in the most recent week (week 48) as shown in the figures below (up to 1 December 2024) with Figure 12 showing a stable picture overall for the current season (the bright red line on the chart). These notifications are now well below 100 a week compared to the peak of over 800 notifications in winter 2022-23.





Figure 11: Rolling 3 Week Average Scarlet Fever Notifications, 2014-2024, Wales (source: PHW)

Figure 12: Rolling 3 Week Average Scarlet Fever Notifications, 2019-2024, Wales (Source: PHW)



C. Science Evidence Advice Winter Modelling

The Science Evidence Advice (SEA) team in Welsh Government have published modelled scenarios for COVID-19, RSV and Influenza for <u>Winter 2024-25</u>. This uses analysis of historical data used to project forward to estimate what we may see in winter 2024/25, contributing to winter planning for NHS Wales. The aim is to estimate the pressures that could be seen by an increase in respiratory viruses and other factors which are typically more prevalent in the winter months than other times of the year. The charts that follow show the scenarios for each disease and plot these against actual data to reveal how well the scenarios are capturing the current pressures on the health system in Wales.

Note that, the modelling is an estimate of what may happen, not a prediction of what will happen.

Our winter modelling uses hospital admissions data from the Patient Episode Data for Wales (PEDW) dataset provided by Digital Health and Care Wales (DHCW). However, due to a lag in clinical coding and receiving PEDW data from DHCW, we use INCET admissions data provided by Public Health Wales (PHW) for our actuals. The data sources differ for a few reasons: the flu and RSV data from PHW includes lab-confirmed results only and includes inpatients only. The PEDW data from DHCW is based on International Classification of Diseases vers. 10 (ICD-10) codes and the definitions may go wider than those used by PHW (e.g. our flu modelling using DHCW's data includes codes for both flu and pneumonia). Therefore, we account for these differences by multiplying the PHW data by the average of the differences in daily sums between the two data sources (3.92 for flu, 4.09 for RSV) last year for hospital admissions.

<u>COVID-19</u>

COVID-19 actuals are currently tracking slightly below scenario 4 which is the Most Likely Scenario (MLS), Following a slight uptick in admissions in October there has been a downward trend into November and December.




Figure 13 Daily COVID-19 Winter 2024-5 admissions scenarios, data until 30 November 2024

Source: Swansea University modelling (Scenarios 1, 2 3), actuals underlying the MLS to 31 March 2024 provided by DHCW, projected MLS scenarios from 1 September 2024 to 31 March 2025 from SEA.

Notes

COVID-19 admissions and occupancy scenarios were created by Swansea University where a new variant emerges gradually every 3 months. The degrees of immune evasion from the variant is given by the scalar value 1, 1.25 and 1.5 and represented as scenarios 1-3. Scenario 4 is the repeat of last year's data from Digital Health and Care Wales. Includes ICD-10 codes U071, U072, U099, U109.

<u>RSV</u>

Adjusted RSV actuals are currently tracking below the MLS and this reflects the significant decrease in the number of RSV admissions in recent weeks.




Figure 14: Daily RSV Winter 2024-5 admissions scenarios, data until 30 November 2024


Source: Raw data to 31 March 2024 provided by DHCW, projected scenarios from 1 September 2024 to 31 March 2025 from SEA


Notes

Scenario 1 reflects trends in the last two years. Scenario 3 assumes pre-pandemic patterns (from 2017/18, 2018/19 and 2019/20). Scenario 2 combines elements from both Scenario 1 and 3 (2017/18, 2018/19, 2019/20, 2022/23 and 2023/24. Scenario 4 is a repeat of last year's data (2023/24). Data includes diagnosis codes J21 to J22 from the ICD-10.

Influenza and Pneumonia

Adjusted Influenza and pneumonia actuals are currently tracking above Scenario 2, reflecting the increase in flu cases as we have moved into the flu season.





Source: Raw data to 31 March 2024 provided by DHCW, projected scenarios from 1 September 2024 to 31 March 2025 from SEA

Notes: Based on the previous seven years of historical data,1 the following scenarios were created for flu admissions and occupancy: Scenario 1 represents the average of non-pandemic years (2017/18, 2018/19, 2019/20, 2022/23 and 2023/24). Scenarios 2 and 3 are obtained by multiplying Scenario 1 by scalars 1.25 and 1.5. Finally, scenario 4, which repeats last year's admissions, is considered the most likely scenario (MLS). Data includes diagnosis codes J09 to J18 (flu and pneumonia) from ICD-10. The adjusted actuals for flu admissions are currently tracking below the most likely scenario.

D. <u>Communicable Disease Situation Update (non-respiratory)</u>

D.1 Norovirus

In the current reporting week (week 48 2024), a total of **46** Norovirus confirmed cases were reported in Welsh residents. This is an increase (21.1%) in reported cases compared to the previous reporting week (week 47 2024), where **38** Norovirus confirmed cases were reported.

In the last 12 week period (09/09/2024 to 01/12/2024) a total of **351** Norovirus confirmed cases were reported in Welsh residents. This is an increase (66.4%) in reported cases compared to the same 12 week period in the previous year (09/09/2023 to 01/12/2023) where **211** Norovirus confirmed cases were reported

In the last 12 weeks (09/09/2024 to 01/12/2024) **208** (59.3%) confirmed Norovirus cases were female and **141** (40.2%) confirmed cases were male. The age groups with the most cases were the 80+ (114 cases) and 70-79 (59 cases) age groups. Sex data were not available for 2 cases.

¹ Admissions during the pandemic years were not included in the scenarios due to very low numbers.




Figure 13: Age and sex distribution of confirmed Norovirus cases in the last 12 weeks (09/09/2024 to 01/12/2024)

Notes: This data from PHW only includes locally-confirmed PCR positive cases of Norovirus in Wales within the 12 week period up until the end of the current reporting week, week 48 2024 (09/09/2024 to 01/12/2024). Under-ascertainment is a recognised challenge in norovirus surveillance with sampling, testing and reporting known to vary by health board. In addition, only a small proportion of community cases are confirmed microbiologically.

E. International Surveillance Update (no change from previous week)

E.1 Mpox Clade 1 (<u>UKHSA Update</u>)

November 29: A new case of Clade Ib mpox has been detected in England, the UK Health Security Agency (UKHSA) can confirm.

The case was detected in Leeds and the individual is now under specialist care at Sheffield Teaching Hospitals NHS Foundation Trust. They had recently returned from Uganda, which is seeing community transmission of Clade Ib mpox. The UKHSA and NHS will not be disclosing any further details about the individual.

The risk to the UK population remains low. We expect to see the occasional imported case of Clade Ib mpox in the UK.

This is the fifth case of Clade Ib mpox confirmed in England in recent weeks. This case has no links to the previous cases identified. All 4 previous cases were from the same household and all have now fully recovered.

Close contacts of the case are being followed up by UKHSA and partner organisations. Any contacts will be offered testing and vaccination as needed and advised on any necessary further care if they have symptoms or test positive.

E.2 Mpox Clade 1b confirmed case in Canada

On November 22, 2024, the Public Health Agency of Canada (PHAC) confirmed the first case of clade I mpox in Canada in an individual in Manitoba. This travel-related case is associated with an ongoing outbreak of clade I mpox in central and eastern Africa. The individual sought medical care for mpox symptoms in Canada shortly after their return and is currently isolating. A public health investigation, including contact tracing, is ongoing.

PHAC is working closely with public health authorities in Manitoba. The National Microbiology Laboratory (NML) notified the province on November 22 that the sample tested positive for mpox clade Ib. While clade II mpox has been circulating in Canada since 2022, this is the first case of clade I mpox confirmed in Canada.

The risk to the general population in Canada remains low at this time. PHAC continues to actively monitor the situation and will provide updated information as it becomes available.

E.3 Mpox Clade 1b confirmed case in USA: CDC Update

The California Department of Public Health confirmed, through laboratory testing, the first known case of clade I mpox in the United States. This case is related to an ongoing outbreak of clade I mpox in Central and Eastern Africa. The risk of clade I mpox to the public remains low, and there continue to be sporadic clade II mpox cases in the United States.

The case was diagnosed in a person who recently travelled from Eastern Africa. The individual was treated shortly after returning to the United States at a local medical facility and released. Since then, the person has isolated at home, is not on treatment specific for mpox, and symptoms are improving. Based on their travel history and symptoms, patient specimens were tested and confirmed for the presence of clade I monkeypox virus. Specimens are being sent to CDC for additional viral characterization. Additionally, CDC is working with the state to identify and follow up with potential contacts.

E.4 Communicable Disease Centre (CDC) USA – Avian Flu in a Child in California

The Centre for Disease Control and Prevention (CDC) has confirmed a human infection with avian influenza A(H5N1) (H5N1 bird flu) in a child in California. This is the first reported avian influenza H5 virus infection in a child in the United States. Consistent with previously identified human cases in the United States, the child reportedly experienced mild symptoms and received flu antivirals. There were low levels of viral material detected in the initial specimen collected, and follow-up testing of the child several days later was negative for H5 bird flu but was positive for other common respiratory viruses. The child is recovering from their illness. An investigation by the California Department of Public Health (CDPH) into the child's possible H5N1 exposure source is ongoing.

During CDPH's investigation, all household members reported having symptoms and specimens were collected from those people. All test results from members of the household were negative for H5 bird flu, and some family members were positive for the same common respiratory viruses as the child. Contact tracing continues, but there is currently no evidence of person-to-person spread of H5N1 bird flu from this child to others. To date, there has been no person-to-person spread identified associated with any of the H5N1 bird flu cases reported in the United States.

E.5 Communicable Disease Centre (CDC) USA – Avian Flu update

18 November, 2024: Since April 2024, CDC, working with state public health departments, has confirmed avian influenza A(H5) virus infections in 52 people in the United States. Twentyone of these cases were associated with exposure to avian influenza A(H5N1) virus -infected poultry and 30 were associated with exposure to infected dairy cows [A][B]. The source of the exposure in one case, which was reported by Missouri on September 6, could not be determined.

The 52 cases include 26 cases among dairy farm workers in California, five of which were confirmed by CDC on November 13 and 14, and one additional case in a poultry farm worker in Oregon. This is the first human case of H5N1 bird flu reported in Oregon. All recent cases have occurred in workers on affected farms. All available data so far suggest sporadic instances of animal-to-human spread. These farm workers all described mild symptoms, many with eye redness or discharge (conjunctivitis). Some workers who tested positive in Washington reported some mild upper respiratory symptoms. None of the workers were hospitalized.

CDC is aware of the human case of H5N1 bird flu reported in Canada and is in communication with the Public Health Agency of Canada (PHAC), which has confirmed that the case was caused by an H5N1 virus that is different than those causing outbreaks in dairy cows and other animals in the United States.